Antigen B modulates anti-inflammatory cytokines in the EAE model of multiple sclerosis.
EAE
cytokines
multiple sclerosis
Antigen B
Journal
Brain and behavior
ISSN: 2162-3279
Titre abrégé: Brain Behav
Pays: United States
ID NLM: 101570837
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
13
12
2021
received:
18
10
2021
accepted:
22
01
2022
pubmed:
31
12
2022
medline:
17
2
2023
entrez:
30
12
2022
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is characterized by the destruction of the blood-brain barrier, loss of myelin sheath, and contribution of inflammatory interleukins such as TNF-alpha, interleukin-17, and interleukin-6. The current study investigated the effect of antigen B of hydatid cyst fluid on the reduction of anti-inflammatory cytokines and nerve conduction velocity in rats with experimental autoimmune encephalomyelitis (EAE)-induced MS. After isolation of antigen B from sterile cyst fluid, the rats were randomly divided into four groups: saline, EAE, EAE + teriflunomide (EAE + TF), and EAE + antigen B (EAE + AngB). The EAE model was induced using cow spinal cord homogenization, in combination with Freund's complete adjuvant. The serum concentration of cytokines including IL-1B and IL-17, IL-10, IL-6, and TNF-X was measured by the ELISA method, and real-time PCR was performed to study gene expression. Electrophysiological, behavioral, and neuropathological tests were also conducted. Nerve conduction velocity and IL-10 concentration were increased in the antigen B group. The results of this study showed that antigen B reduced the inflammatory component of the EAE MS animal model by modulating the immune system compared to teriflunomide, which eventually led to a reduction in symptoms at the behavioral and electrophysiological level. It seems that antigen B plays a critical role in regulating immunity and it can be used as a possible therapeutic agent to modulate the immune system in MS patients. It might be rational to consider hydatid cyst fluid antigen as a modifier in MS.
Identifiants
pubmed: 36582052
doi: 10.1002/brb3.2874
pmc: PMC9927863
doi:
Substances chimiques
Cytokines
0
teriflunomide
1C058IKG3B
Interleukin-10
130068-27-8
Interleukin-6
0
Anti-Inflammatory Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2874Informations de copyright
© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC.
Références
Eur J Immunol. 2010 Jun;40(6):1525-37
pubmed: 20405478
Immunobiology. 2006;211(1-2):3-9
pubmed: 16446166
Iran J Immunol. 2017 Mar;14(1):35-50
pubmed: 28341817
Clin Dev Immunol. 2013;2013:948976
pubmed: 23840244
Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):65-70
pubmed: 16914097
Biologicals. 2018 Jan;51:1-11
pubmed: 29100669
J Infect. 2015 Mar;70(3):299-306
pubmed: 25444973
Neurosci Lett. 2019 Jun 21;704:153-158
pubmed: 30974232
Parasite Immunol. 2000 Oct;22(10):475-85
pubmed: 11012973
Trends Mol Med. 2019 Feb;25(2):112-123
pubmed: 30578090
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Acta Neuropathol. 2019 May;137(5):757-783
pubmed: 30847559
J Autoimmun. 2014 Feb-Mar;48-49:134-42
pubmed: 24524923
Biomedicines. 2020 Jun 08;8(6):
pubmed: 32521719
Postepy Hig Med Dosw (Online). 2017 Jun 30;71(0):551-563
pubmed: 28665284
Acta Trop. 2017 Feb;166:7-15
pubmed: 27983971
Brain Behav Immun. 2004 Jan;18(1):7-12
pubmed: 14651941
Brain Behav. 2023 Feb;13(2):e2874
pubmed: 36582052
Parasit Vectors. 2016 Feb 04;9:69
pubmed: 26846700
Neuron. 2018 Feb 21;97(4):742-768
pubmed: 29470968
Eur Cytokine Netw. 2008 Sep;19(3):142-8
pubmed: 18775805
Brain Pathol. 2017 Mar;27(2):123-137
pubmed: 27792289
J Interferon Cytokine Res. 2007 Sep;27(9):781-7
pubmed: 17892399
mBio. 2013 Jun 18;4(3):e00264-13
pubmed: 23781069
Neurol Clin. 2018 Feb;36(1):1-11
pubmed: 29157392
Immunology. 2006 Jun;118(2):271-8
pubmed: 16771863
J Neuroinflammation. 2014 Jun 03;11:98
pubmed: 24889886
Acta Neuropathol Commun. 2020 May 12;8(1):66
pubmed: 32398070
Eur Neurol. 2013;70(5-6):356-63
pubmed: 24192707
Acta Neuropathol. 2014 Aug;128(2):191-213
pubmed: 24952885
Exp Parasitol. 2008 Aug;119(4):483-489
pubmed: 18329023
JCI Insight. 2020 Nov 5;5(21):
pubmed: 33148886
Am J Trop Med Hyg. 1971 Jul;20(4):569-74
pubmed: 5568124
Infect Immun. 2001 Jan;69(1):288-96
pubmed: 11119517
Vet Parasitol. 2010 Nov 24;174(1-2):2-11
pubmed: 20888694
Sci Rep. 2021 Mar 18;11(1):6233
pubmed: 33737535
Oxid Med Cell Longev. 2011;2011:976948
pubmed: 22191015
PLoS Negl Trop Dis. 2012;6(2):e1516
pubmed: 22363826
Parasite Immunol. 1996 Nov;18(11):571-8
pubmed: 9226695
J Neuroinflammation. 2017 Jun 9;14(1):117
pubmed: 28599652
Parasit Vectors. 2014 Nov 20;7:522
pubmed: 25409540
Iran J Immunol. 2011 Dec;8(4):236-43
pubmed: 22201621
Braz J Med Biol Res. 2017 Jul 03;50(7):e6071
pubmed: 28678921
PLoS Negl Trop Dis. 2010 Aug 10;4(8):e784
pubmed: 20706625
BMC Immunol. 2015 Aug 13;16:44
pubmed: 26268402
J Neuroinflammation. 2017 Jan 23;14(1):19
pubmed: 28115010
J Autoimmun. 2015 Nov;64:13-25
pubmed: 26142251
Br J Pharmacol. 2011 Oct;164(4):1079-106
pubmed: 21371012
Lancet Neurol. 2021 Feb;20(2):136-149
pubmed: 33484648
J Inflamm (Lond). 2015 Mar 17;12:19
pubmed: 25844068
Mol Biol Rep. 2019 Dec;46(6):6135-6146
pubmed: 31555971
P T. 2012 Mar;37(3):175-84
pubmed: 22605909
Infect Immun. 2007 Apr;75(4):1667-78
pubmed: 17210662
Acta Trop. 2015 Jan;141(Pt B):235-43
pubmed: 24686096
Parasite Immunol. 2003 Mar;25(3):161-8
pubmed: 12911524
AIMS Neurosci. 2021 Feb 5;8(2):239-253
pubmed: 33709027
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):570-88
pubmed: 22583443
Parasitol Res. 2004 Apr;92(6):506-12
pubmed: 15007640
Mult Scler. 2015 Jan;21(1):8-21
pubmed: 25480864
Interdiscip Perspect Infect Dis. 2009;2009:474368
pubmed: 19888428